Flexion Therapeutics (NSDQ:FLXN) touted data today from a Phase II trial assessing the bilateral dosing of its extended-release triamcinolone acetonide injection in people with bilateral osteoarthritis.
The study found that bilateral injections of Flexion’s Zilretta therapy resulted in lower plasma concentrations of triamcinolone acetonide compared to immediate-release triamcinolone acetonide in crystalline suspension (TAcs). The company also noted that concurrent administration of Zilretta was well tolerated among the study’s participants.
Get the full story at our sister site, Drug Delivery Business News.
The post Flexion reports data from Phase II bilateral osteoarthritis trial appeared first on MassDevice.
from MassDevice https://ift.tt/2yU4AXX
Cap comentari:
Publica un comentari a l'entrada